Chiron is strongly focused on developing high-value products for cancer and infectious disease. We continue to build upon our cancer franchise, which has three dimensions: immune system modulators (recombinant proteins), monoclonal antibodies, and novel anti-cancer agents (small molecules). In the infectious disease area, we have a range of breakthrough products spanning all three of our business units, and are investing to fully develop each of our product franchises. To sustain future growth, we are also strengthening our pipeline through organic development, acquisition, and in-licensing. Chiron BioPharmaceuticals manufactures and markets high-value therapeutic products. Our leading products include: TOBI® (tobramycin solution for inhalation) for lung infections in cystic fibrosis patients; Proleukin® (aldesleukin) for kidney and skin cancer; and Betaseron® (inteferon beta-1b) for multiple sclerosis. Chiron Vaccines, the fifth largest vaccine business in the world, currently offers more than 30 novel and conventional vaccines for adults and children. We provide a range of novel high-value vaccines, including Menjugate™, a conjugated vaccine against meningococcal C disease; Fluad™, an adjuvanted flu vaccine; Begrivac™, the first preservative-free flu vaccine; and Encepur™, a vaccine against tick-borne encephalitis. Chiron Blood Testing is a leading provider of products used worldwide by the blood banking industry to help ensure the safety of the world’s blood supply. With our collaborator, Gen-Probe Incorporated, we are developing and commercializing innovative and highly sensitive NAT (nucleic acid testing) blood screening assays, including the Procleix™ HIV-1/HCV Assay for human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV). Through our joint business with Ortho-Clinical Diagnostics, we develop and market a line of immunoassay screening and supplemental tests for infectious diseases. Chiron’s large and growing portfolio of intellectual property, led by the company’s pioneering accomplishments in HIV and HCV, has resulted in numerous collaborations and licensing agreements with major companies, particularly in the areas of blood screening and diagnostics. Through partnerships with such companies as F. Hoffmann-La Roche, Abbott Laboratories, and Bayer, Chiron is helping to bring important new medical advances to the market.